Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias

Acta Oncologica

Volumn 49, Issue 1, 2010, Pages 109-110

  Stagno, Fabio ^a   Vigneri, Paolo ^a,b   Fabro, Vittorio Del ^a   Stella, Stefania ^a   Restuccia, Nunzio ^b   Giallongo, Cesarina ^a   Massimino, Michele ^a   Berretta, Salvatore ^a   Pennisi, Maria Stella ^a   Tibullo, Daniele ^a   Tirrò, Elena ^a   Buscarino, Calogero ^b   Messina, Angelo ^a   Raimondo, Francesco Di ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CETUXIMAB; DASATINIB; HYDROXYUREA; IMATINIB;

ADULT; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; LETTER; LEUKEMIA REMISSION; LEUKOPENIA; LOADING DRUG DOSE; MALE; MOUTH CARCINOMA; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TONGUE CARCINOMA; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; EAR DISEASES; FUSION PROTEINS, BCR-ABL; HUMANS; KERATOACANTHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; NEOPLASMS, SECOND PRIMARY; PYRIMIDINES; RADIOTHERAPY; SCALP; THIAZOLES; TONGUE NEOPLASMS; VOCAL CORDS;

EID: 76649111398     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903302913     Document Type: Letter

References (5)

1. Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008;20:104-11.
2. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
5. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: A growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007;16:566-71.